French company Carmat has secured conditional approval from the US Food and Drug Administration (FDA) to initiate the second cohort of its early feasibility study (EFS) in the US with the Aeson ...

It reflects Aeson® artificial heart’s quality and performance and its potential to address the unmet need expressed by healthcare professionals and patients around the world. This authorization ...